News | March 05, 2024
Biocon Biologics secures Canada market entry date for YESAFILI
This agreement paves the way for the introduction of YESAFILI into the Canadian market
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
AMI to become part of Enpro’s Sealing Technologies Segment
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
The company has entered into a three-year Deferred Prosecution Agreement
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Subscribe To Our Newsletter & Stay Updated
